Cardiac Biomarkers Market, By Product Type (Myocardial Muscle Creatine Kinase, Myoglobin, Troponins, Brain Natriuretic Peptide or NT-proBNP, Ischemia-modified Albumin, and Others), By Application (Myocardial Infarction, Congestive Heart Failure, Acute Coronary Syndrome, Atherosclerosis, and Others), By Location of Testing (Laboratory Testing and Point of Care Testing), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

Published In : Jun 2024

Code : CMI4576

Pages :186

Formats :

Excel and PDF

Industry : Biotechnology

Key Developments

On 27 January 2024, An international academic collaboration, led by Mr.Johns Hopkins University, the Chinese University of Hong Kong, and Lund University, has identified 13 biomarkers that significantly enhance the accuracy of predicting cardiovascular disease risk in individuals with type 2 diabetes. Despite type 2 diabetes doubling the risk of cardiovascular disease, traditional risk scores are outdated and ineffective in diverse populations, posing a challenge for clinicians in determining the most at-risk individuals.
On 29 February 2024, According to data published by Healthline Media UK Ltd, A recent study has pinpointed six biomarkers in individuals with rheumatoid arthritis (RA) that correlate with changes in artery inflammation, potentially aiding in predicting heart disease risk more accurately than current methods. Published in the Journal of the American Heart Association, the study analyzed 109 participants and identified these biomarkers as indicators of heightened cardiovascular disease risk in RA patients.
In October 2023 Mindray, a global provider of medical devices and solutions, has unveiled two new cardiac biomarkers, hs-cTnI and NT-proBNP, expanding its range of tools for diagnosing and treating cardiovascular diseases. The announcement was made through a recent statement, marking the global launch of these additions to Mindray's portfolio.
In September 2022, SRL Diagnostics, Diagnostics Company in India introduced "Heart Assure," a specialized examination designed to forecast an individual's likelihood of experiencing a cardiac event. This test utilizes high-sensitivity troponin I, a straightforward blood test, to accurately gauge the risk of cardiac injury by generating a heart health risk score.
In June 2022, SCIEX, a prominent player in life science analytical technologies and a subsidiary of Danaher Corporation, unveiled the Zeno SWATH DIA, marking a substantial advancement in biomarker exploration and application workflows.